In a first trial of androgen receptor inhibitor, enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer, pharmacokinetics and tolerability of single agentenzalutamide have shown to be similar to that reported in men.
Estradiol remained low in combination with exemestane, according to the results presented by Dr Tiffany Traina of the Memorial Sloan-Kettering Cancer Center, New York, USA.
Read the article in full here
Source: ESMO
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.